NIH Just Killed Foreign Subawards. The PF5 Grant Type Rewrites the Rules for International Research.

For forty years, the mechanics of international research collaboration at the National Institutes of Health followed a simple pattern. A domestic university won a grant. Part of the budget included a subaward to a foreign institution — a lab in London, a clinical site in Nairobi, a data consortium in Geneva. The foreign money flowed through the domestic institution, which was responsible for oversight, compliance, and reporting.

That system is now dead.

Starting with due dates on or after January 25, 2026, NIH no longer accepts applications that request funds for foreign components using the traditional subaward structure. In its place, the agency has created an entirely new activity code — the PF5, or Collaborative International Research Project — that fundamentally restructures how American researchers partner with scientists abroad. Foreign collaborators will no longer receive money through the domestic PI's grant. They will receive their own separate awards, tracked independently, with their own grant numbers and their own compliance obligations.

As Granted News reported, this is the most significant structural change to NIH's international funding apparatus in decades. But the news brief only scratched the surface. The implications run deep — for researchers who depend on international partnerships, for universities that administer these grants, and for the broader trajectory of American science in a world where the most important problems demand cross-border collaboration.

Why NIH Pulled the Trigger

The foreign subaward model had a transparency problem that had been building for years.

When a domestic institution included a foreign subaward in an R01 or U01, NIH knew the total budget but had limited visibility into how the foreign component spent its allocation. The domestic institution was technically responsible for monitoring the foreign sub-recipient, but in practice, oversight varied widely. Some universities maintained rigorous sub-recipient monitoring programs. Others treated foreign subawards as paperwork exercises — send the money, collect the progress report, move on.

This opacity became politically untenable as concerns about foreign influence in U.S.-funded research intensified. Congressional inquiries into research security, the Department of Justice's China Initiative (and its aftermath), and Executive Order 14332's emphasis on grant oversight all created pressure for NIH to demonstrate that it knew exactly where every federal research dollar went — including dollars that crossed borders.

The PF5 mechanism is NIH's answer. By disaggregating the foreign component into a separate award with its own grant number, NIH gains direct oversight of the foreign institution. The money no longer passes through the domestic university. NIH tracks it directly, reviews it independently, and can modify or terminate it without touching the domestic PI's primary award.

How the PF5 Actually Works

The mechanics of the PF5 represent a genuine departure from how researchers have structured international collaborations for decades.

Under the new system, a domestic PI who wants to collaborate with a foreign institution submits a PF5 application that contains three components: an Overall Component describing the collaboration's objectives and rationale, a Research Project component detailing the domestic institution's scientific work, and an International Project component for each foreign collaborator's contribution.

After peer review, if the application is selected for funding, NIH disaggregates it. The domestic Research Project becomes a standard NIH award. Each International Project is pulled out and issued a separate grant number under a new RF2 activity code, with the foreign organization listed as the direct recipient. The two awards are linked in NIH's systems but managed independently.

This disaggregation has cascading consequences. The foreign institution now has a direct relationship with NIH — meaning it must comply with NIH's terms and conditions, submit its own progress reports, and manage its own budget. The domestic PI is no longer the financial intermediary. And NIH's Office of Extramural Research can audit the foreign component without going through the domestic institution's sponsored programs office.

What the PF5 Excludes

Not every international element triggers the PF5 requirement, and understanding the boundaries matters for planning.

The PF5 mechanism is specifically designed for funded international collaborations — situations where federal dollars flow to a foreign institution to conduct a defined scope of work. It does not apply to projects where the international component consists of:

• Hiring a foreign consultant for advisory input
• Purchasing equipment or supplies from a foreign vendor
• Unfunded collaborations where a foreign scientist contributes expertise without receiving NIH dollars
• Foreign travel by domestic personnel

This means researchers who maintain informal international networks — sharing data, co-authoring papers, attending each other's conferences — can continue operating under existing grant mechanisms. The PF5 applies only when money moves.

But for the substantial number of NIH-funded projects that do include funded foreign components — particularly in global health, infectious disease, climate-related health research, and genomics — the PF5 is now mandatory. There is no grandfathering provision for existing awards, though active grants with foreign subawards will complete under their current terms.

The Budget Architecture Shift

The financial structure of PF5 awards introduces complexities that university grants offices are still working through.

Under the old subaward model, the domestic institution's budget included the foreign component as a line item. Indirect costs on the first $25,000 of each subaward flowed to the domestic institution. The domestic institution's F&A rate applied to its portion of the project. This was administratively familiar, and grants offices had decades of experience managing it.

Under the PF5, the foreign component has its own budget, submitted as part of the PF5 application but managed independently after disaggregation. The domestic institution no longer collects indirect costs on the foreign component. The foreign institution negotiates (or accepts a default) indirect cost rate directly with NIH.

For universities that administer large portfolios of internationally collaborative grants, this represents a measurable revenue reduction. The indirect cost recovery on foreign subawards was never enormous on a per-grant basis, but aggregated across dozens or hundreds of awards, it added up. Research-intensive institutions with major global health programs will feel this most acutely.

The flip side is reduced administrative burden. Domestic institutions will no longer be responsible for sub-recipient monitoring of foreign partners — the auditing, financial reviews, and compliance checks that consumed staff time. Whether the administrative savings offset the indirect cost revenue loss depends on the institution's specific portfolio and overhead structure.

The Timing Problem

The first PF5 deadline for standard NIH applications is May 25, 2026 — less than three months away as of this writing. AIDS-related applications have a September 7, 2026 deadline. The first awards are expected to begin in April 2027.

This timeline creates a practical challenge. Researchers who submitted R01 or other applications before January 25, 2026 with traditional foreign subawards will have those processed under the old rules. But anyone planning a new submission with an international component must now use the PF5 — and many investigators have never seen the PF5 application format, let alone written one.

The application is more complex than a standard R01. The three-component structure requires the domestic PI to articulate the collaboration's rationale in the Overall Component, detail their own work in the Research Project, and ensure the foreign collaborator writes a credible International Project section that can survive disaggregation into a standalone award. This last point is critical: the International Project must be scientifically coherent on its own, because after disaggregation, NIH reviewers and program officers will evaluate it independently.

For researchers accustomed to writing a single application with a foreign subaward budget page tucked into the appendix, this is a fundamentally different exercise.

What This Means for Global Health Research

The fields most affected by the PF5 transition are those where international collaboration is not optional but definitional.

Global health research — HIV/AIDS, tuberculosis, malaria, neglected tropical diseases, pandemic preparedness — relies on clinical sites, population cohorts, and biological samples that exist only in specific countries. An HIV vaccine trial needs enrollment sites in sub-Saharan Africa. A study of drug-resistant TB requires samples from Southeast Asian clinical networks. A genomics consortium studying population diversity needs partners on every continent.

These projects cannot be restructured to avoid international funding. The PF5 is not a barrier to this work — NIH has been explicit that it wants to continue funding international collaborations — but it does add complexity. Foreign institutions that previously received subawards without having a direct NIH relationship must now register, comply, and report independently. In countries with limited research administration infrastructure, this is a significant capacity challenge.

The practical impact will vary by partner. A major European research university with an established grants office can handle direct NIH compliance without difficulty. A district hospital in rural Mozambique that serves as a clinical enrollment site may struggle. The PF5 structure implicitly favors well-resourced international partners, which could concentrate international collaboration among elite institutions and reduce the diversity of the global research network.

Navigating the Transition

For researchers preparing PF5 applications, several strategic considerations emerge from the early implementation details.

Start conversations with foreign partners now. The International Project component requires the foreign institution to articulate its own scientific plan, budget, and compliance capacity. This is not something you can draft on their behalf and submit at the last minute. Foreign partners need time to understand the new structure, register appropriately, and prepare their sections.

Justify the international component explicitly. NIH guidance for PF5 applications emphasizes that projects must demonstrate that international collaboration provides "unusual talent, resources, populations, or environmental conditions not readily available in the United States." The bar for justification is higher than it was under the subaward model, where including a foreign partner was largely a budget decision rather than a scientific argument.

Budget for administrative transition costs. The first cycle of PF5 applications will require more grants office staff time than traditional submissions. Universities should plan for the additional workload rather than assuming existing staff can absorb it.

Consider the disaggregation implications for project management. When the foreign component becomes a separate award, the domestic PI's formal authority over the international partner changes. Collaboration agreements, data sharing arrangements, and intellectual property provisions should be negotiated before submission, not after award.

The Broader Signal

The PF5 mechanism is not an isolated policy change. It fits within a broader pattern of NIH restructuring that prioritizes transparency, accountability, and security over administrative simplicity.

Congress's decision to preserve $48.7 billion for NIH while rejecting a proposed 40 percent cut shows continued bipartisan support for biomedical research. But that support comes with strings — and the PF5 is one of them. Legislators who fought to maintain NIH funding did so partly by pointing to enhanced oversight mechanisms like the PF5 as evidence that taxpayer dollars would be tracked more rigorously.

For the research community, the message is clear: international collaboration remains valued, but the era of minimal oversight for foreign-directed federal research dollars is over. The PF5 creates more work for everyone involved — researchers, grants offices, foreign partners, and NIH staff. Whether it also creates better science, or simply more paperwork, will depend on how the implementation unfolds.

The May 25 deadline is approaching. Researchers with international partnerships should not wait to see how others handle the transition. The time to restructure proposals, engage foreign collaborators, and learn the PF5 format is now — and tools like Granted can help you navigate the new requirements and build compliant applications before the first wave of submissions arrives.